Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer

  • Gianpaolo Perletti | gianpaolo.perletti@uninsubria.it Department of Biotechnology and Life Sciences, Section of Medical and Surgical Sciences, Università degli Studi dell’Insubria, Busto A., Varese, Italy; Department of Basic Medical Sciences, Ghent University, Ghent, Belgium.

Abstract

Not available.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2016-03-31
Info
Issue
Section
Letters to the Editor
Keywords:
TROPIC, Cabazitaxel, Mitoxantrone
Statistics
  • Abstract views: 1387

  • PDF: 849
How to Cite
Perletti, G. (2016). Reply to: Clarification to provide further understanding of the conduct and design of TROPIC: A Phase 3 trial of cabazitaxel versus mitoxantrone in patients with metastatic castration-resistant prostate cancer. Archivio Italiano Di Urologia E Andrologia, 88(1), 74-75. https://doi.org/10.4081/aiua.2016.1.74